It is known that β-lactam antibiotics exhibit time-dependent bactericidal activity. Several studies have found continuous infusion of meropenem more effective than intermittent infusion in maintaining constant serum concentrations in excess of the minimum inhibitory concentration. However, limited data exist on the clinical efficacy of meropenem administered by continuous infusion.
Objective:
To evaluate the clinical efficacy of continuous versus intermittent infusion of meropenem for the treatment of ventilator-associated pneumonia (VAP) due to gram-negative bacilli.
Methods:
A retrospective cohort study was conducted of patients with VAP caused by gram-negative bacilli who received initial empiric antibiotic therapy with meropenem. We analyzed 2 contemporary cohorts: one group received meropenem by continuous infusion (1 g over 360 min every 6 h), the other by intermittent infusion (1 g over 30 min every 6 h). The administration method was prescribed according to the physician's discretion. Patients received meropenem plus tobramycin for 14 days.
Results:
There were no significant differences between patient groups with regard to gender, age, APACHE-II at intensive care unit admission, diagnosis, microorganism responsible for VAP, or organ dysfunction severity at the time VAP was suspected. The group receiving medication by continuous infusion showed a greater clinical cure rate than the group treated with intermittent infusion (38 of 42, 90.47%, vs 28 of 47, 59.57%, respectively, with OR 6.44 [95% Cl 1.97 to 21.05; p < 0.001]).
Conclusions:
Meropenem administered by continuous infusion may have more clinical efficacy than intermittent infusion.
LeuHSKaiserDLMoriMWoolsonRFWenzelRP. Hospital-acquired pneumonia. Attributable mortality and morbidity. Am J Epidemiol1989;129:1258–67.
2.
FagonJYChastreJHanceAJMontraversPNovaraAGibertC. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med1993;94:281–8.
3.
HeylandDKCookDJGriffithLEKeenanSPBrun-BuissonC. For the Canadian Critical Care Trials Group. The attributable morbidity and mortality of ventilator associated pneumonia in the critically ill patient. Am J Respir Crit Care Med1999;159:1249–56.
4.
RhombergPRJonesRN. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis2003;47:365–72.
5.
DrusanoGL. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother1988;32:289–97.
6.
CraigWAEbertSC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother1992;36:2577–83.
7.
TurnidgeJD. The pharmacodynamics of beta-lactams. Clin Infect Dis1998;27:10–22.
8.
JacobsMR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect2001;7:589–96.
9.
BurgessDS. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest1999;115(suppl 3):19S–23S.
10.
JaruratanasirikulSSriwiriyajanSPunyoJ. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother2005;49:1337–9.
11.
DandekarPKMaglioDSutherlandCANightingaleCHNicolauDP. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy2003;23:988–91.
12.
JaruratanasirikulSSriwiriyajanS. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection. J Antimicrob Chemother2003;52:518–21.
13.
KutiJLDandekarPKNightingaleCHNicolauDP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol2003;43:1116–23.
14.
KruegerWABulittaJKinzing-SchippersM. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother2005;49:1881–9.
15.
KeilSWiedemannB. Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model. Antimicrob Agents Chemother1997;41:1215–9.
16.
ThalhammerFTraunmullerFEl MenyawiI. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother1999;43:523–37.
17.
ElkhailiHPeterJDPompeiD. Pharmacokinetics in vivo and pharmacodynamics ex vivo/in vitro of meropenem and cefpirome in the Yucatan micropig model: continuous infusion versus intermittent injection. Clin Microbiol Infect1998;4:18–26.
18.
DomenigCTraunmullerFKozekS. Continuous beta-lactam antibiotic therapy in a double-lung transplanted patient with a multidrug-resistant Pseudomonas aeruginosa infection. Transplantation2001;71:744–5.
19.
CapitanoBNicolauDPPotoskiBA. Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections. Pharmacotherapy2004;24:803–7.
20.
KutiJLMossKMNicolauDPKnauftRF. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy2004;24:1641–5.
21.
CockcroftDWGaultMH. Prediction of creatinine clearance from serum creatinine. Nephron1976;16:31–41.
22.
TakeuchiYTakebayashiYSunagawaM. The stability of a novel carbapenem antibiotic, meropenem (SM-7338), in a solid state formulation for injection. Chem Pharm Bull1993;41:1998–2002.
23.
ViaeneEChanteuxHServaisHMingeot-LeclercqMPTulkensPM. Comparative stability studies of antipseudomonal betalactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother2002;46:2327–32.
24.
PatelPRCookSE. Stability of meropenem in intravenous solution. Am J Health Syst Pharm1997;54:412–21.
25.
JaruratanasirikulSSriwiriyajanS. Stability of meropenem in normal saline solution after storage at room temperature. Southeast Asian J Trop Med Public Health2003;34:627–9.
26.
Package insert Meronem (meropenem). Caponago, Italy: AstraZeneca, April 1, 2002.
27.
NicolauDPFreemanCDBelliveauPPNightingaleCHRossJWQuintilianiR. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother1995;39:650–5.
28.
VincentJLMorenoRTakalaJ. The Sepsis-related Organ Failure Assessment (SOFA) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-related Problems of the European Society of Intensive Care Medicine. Intensive Care Med199622:707–10.
29.
Brun-BuissonCSoletJPSchweichHBriereSPetitC. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin vs ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group. Clin Infect Dis1998;26:346–54.
30.
KollefMHSilverPMurphyDMTrovillionE. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest1995;108:1655–62.
31.
FinkMPSnydmanDRNiedermanMS. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother1994;38:547–57.
MattoesHMKutiJLDrusanoGLNicolauDP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther2004;26:1187–98.
34.
BurgessDS. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis2005;40(suppl 2):S99–104.
35.
LomaestroBMDrusanoGL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother2005;49:461–3.
